Lymphocyte abnormalities predicting a poor prognosis in Hodgkin's disease. A long-term follow-up
Open Access
- 15 August 1991
- Vol. 68 (4) , 768-775
- https://doi.org/10.1002/1097-0142(19910815)68:4<768::aid-cncr2820680418>3.0.co;2-1
Abstract
No abstract availableKeywords
This publication has 30 references indexed in Scilit:
- MOPP chemotherapy versus extended-field radiotherapy in the management of pathological stages I-IIA Hodgkin's disease.Journal of Clinical Oncology, 1989
- Treatment of progressive Hodgkin's disease with intensive chemoradiotherapy and autologous bone marrow transplantationBlood, 1989
- Successful treatment of refractory Hodgkin's disease by high-dose combination chemotherapy and autologous bone marrow transplantationBlood, 1989
- Twenty years of MOPP therapy for Hodgkin's disease.Journal of Clinical Oncology, 1986
- Alternating Non-Cross-Resistant Combination Chemotherapy or MOPP in Stage IV Hodgkin's DiseaseAnnals of Internal Medicine, 1986
- High-Dose Cyclophosphamide, Carmustine, and Etoposide and Autologous Bone Marrow Transplantation for Relapsed Hodgkin's DiseaseAnnals of Internal Medicine, 1986
- The management of stage I--II Hodgkin's disease with irradiation alone or combined modality therapy: the Stanford experienceBlood, 1982
- Lymphocyte function in untreated Hodgkin's disease: An important predictor of prognosisBritish Journal of Cancer, 1982
- Prognostic Factors in Hodgkin's DiseaseScandinavian Journal of Haematology, 1978
- Combination Chemotherapy in the Treatment of Advanced Hodgkin's DiseaseAnnals of Internal Medicine, 1970